Abstract:Sleep fragmentation (SF) can increase inflammation and production of reactive oxygen species (ROS), leading to metabolic dysfunction. SF is associated with inflammation of adipose tissue and insulin resistance. Several studies have suggested that melatonin may have beneficial metabolic effects due to activating AMP-activated protein kinase (AMPK). However, it is unclear whether melatonin affects the AMPK signaling pathway in SF-induced metabolic dysfunction. Therefore, we hypothesize that SF induces metabolic impairment and inflammation in white adipose tissue (WAT), as well as altered intracellular homeostasis. We further hypothesize that these conditions could be improved by melatonin treatment. We conducted an experiment using adult male C57BL/6 mice, which were divided into three groups: control, SF, and SF with melatonin treatment (SF+Mel). The SF mice were housed in SF chambers, while the SF+Mel mice received daily oral melatonin. After 12 weeks, glucose tolerance tests, insulin tolerance tests, adipose tissue inflammation tests, and AMPK assessments were performed. The SF mice showed increased weight gain, impaired glucose regulation, inflammation, and decreased AMPK in WAT compared to the controls. Melatonin significantly improved these outcomes by mitigating SF-induced metabolic dysfunction, inflammation, and AMPK downregulation in adipose tissue. The therapeutic efficacy of melatonin against cardiometabolic impairments in SF may be due to its ability to restore adipose tissue homeostatic pathways.

What problem does this paper attempt to address?

### Problems the paper attempts to solve This paper aims to explore the potential role and mechanism of melatonin in improving metabolic dysfunction caused by sleep fragmentation (SF). Specifically, the researchers hypothesized: 1. **Effects of sleep fragmentation**: Sleep fragmentation will lead to metabolic dysfunction and increased inflammatory response in white adipose tissue (WAT), thereby affecting blood - glucose homeostasis and insulin sensitivity. 2. **Role of melatonin**: Melatonin can improve metabolic dysfunction caused by sleep fragmentation by reducing inflammation and activating the AMPK signaling pathway. To verify this hypothesis, the researchers used adult male C57BL/6 mice and divided them into three groups: - **Control group**: Mice reared under normal conditions. - **Sleep fragmentation group (SF group)**: Mice reared under sleep fragmentation conditions. - **Sleep fragmentation plus melatonin treatment group (SF + Mel group)**: Mice reared under sleep fragmentation conditions and orally administered melatonin daily. Through a 12 - week experiment, the researchers conducted glucose tolerance tests (GTT), insulin tolerance tests (ITT), adipose tissue inflammation tests, and AMPK evaluations to observe the metabolic changes and changes in AMPK activity in each group of mice. ### Main findings 1. **Body weight changes**: Mice in the SF group began to gain significant weight after 4 weeks, and both body weight and body weight gain were significantly higher than those in the control group after 12 weeks. However, after 12 weeks of melatonin treatment, the body weight and body weight gain of mice in the SF + Mel group were significantly reduced. 2. **Lipid profile changes**: After 12 weeks, the triglyceride (TG) level in the SF group was significantly higher than that in the control group, while the TG level in the SF + Mel group was significantly reduced. 3. **Blood - glucose regulation**: Mice in the SF group showed significantly high blood - glucose levels in GTT and ITT after 12 weeks, while the blood - glucose level in the SF + Mel group was significantly reduced, and the area under the glucose curve (AUC) was also significantly reduced. 4. **C - peptide level**: The C - peptide level in the SF group was significantly lower than that in the control group, while the C - peptide level in the SF + Mel group was significantly increased after 12 weeks of melatonin treatment. 5. **ROS and inflammation**: The levels of ROS and the number of F4/80 - positive cells in the WAT of mice in the SF group were significantly increased, while the levels of ROS and the number of F4/80 - positive cells in the SF + Mel group were significantly reduced. Gene expression analysis showed that the expressions of pro - inflammatory cytokines IL - 1β and TNF - α, as well as macrophage markers F4/80 and MCP - 1 in the SF group were significantly increased, and melatonin treatment significantly reduced the expressions of these genes. In summary, this paper experimentally verified the potential role of melatonin in improving metabolic dysfunction caused by sleep fragmentation, especially by reducing inflammation and activating the AMPK signaling pathway.

Melatonin Improves Glucose Homeostasis and Insulin Sensitivity by Mitigating Inflammation and Activating AMPK Signaling in a Mouse Model of Sleep Fragmentation

Melatonin improved glucose homeostasis is associated with the reprogrammed gut microbiota and reduced fecal levels of short-chain fatty acids in db/db mice

Melatonin improves cardiac function in a mouse model of heart failure with preserved ejection fraction

Melatonin Ameliorates Hypoglycemic Stress-Induced Brain Endothelial Tight Junction Injury by Inhibiting Protein Nitration of TP53-induced Glycolysis and Apoptosis Regulator.

Melatonin Protects Endothelial Progenitor Cells Against AGE-induced Apoptosis Via Autophagy Flux Stimulation and Promotes Wound Healing in Diabetic Mice

Dietary Melatonin Protects Against Behavioural, Metabolic, Oxidative, and Organ Morphological Changes in Mice that are Fed High-Fat, High- Sugar Diet

Inflammaging, Metabolic Syndrome and Melatonin: A Call for Treatment Studies

Protective effect of melatonin against metabolic disorders and neuropsychiatric injuries in type 2 diabetes mellitus mice

Melatonin Alleviates Glucose and Lipid Metabolism Disorders in Guinea Pigs Caused by Different Artificial Light Rhythms

Melatonin stimulates glucose transport via insulin receptor substrate-1/phosphatidylinositol 3-kinase pathway in C2C12 murine skeletal muscle cells

Chronic melatonin treatment improves obesity by inducing uncoupling of skeletal muscle SERCA-SLN mediated by CaMKII/AMPK/PGC1α pathway and mitochondrial biogenesis in female and male Zücker diabetic fatty rats

Melatonin reprogramming of gut microbiota improves lipid dysmetabolism in high‐fat diet‐fed mice

Chronic Sleep Disruption Alters Gut Microbiota, Induces Systemic and Adipose Tissue Inflammation and Insulin Resistance in Mice

Melatonin ameliorates hepatic steatosis by inhibiting NLRP3 inflammasome in db/db mice

Melatonin Ameliorates Neuropsychiatric Behaviors, Gut Microbiome, and Microbiota-Derived Metabolites in Rats with Chronic Sleep Deprivation

Melatonin Attenuates Diabetic Myocardial Microvascular Injury through Activating the AMPK/SIRT1 Signaling Pathway

Cardiometabolic Changes in Sirtuin1-Heterozygous Mice on High-Fat Diet and Melatonin Supplementation

Melatonin Enhances the Mitochondrial Functionality of Brown Adipose Tissue in Obese—Diabetic Rats

Melatonin Efficacy in Obese Leptin-Deficient Mice Heart

Melatonin ameliorates anxiety-like behaviors induced by sleep deprivation in mice: Role of oxidative stress, neuroinflammation, autophagy and apoptosis

Melatonin Alleviates Liver Mitochondrial Dysfunction in Leptin-Deficient Mice